The U.S. Food and Drug Administration has approved Jascayd (nerandomilast) tablets for the treatment of progressive pulmonary ...
Please provide your email address to receive an email when new articles are posted on . Nerandomilast is the first oral preferential phosphodiesterase 4B inhibitor approved for progressive pulmonary ...
FDA Clears New Lung DrugThe US Food and Drug Administration has approved Jascayd (nerandomilast) tablets for adults with progressive pulmonary fibrosi.
Progressive pulmonary fibrosis (PPF) is a life-threatening, progressive lung condition, causing a continuous decline in lung function. 1, 2 Affecting up to 100,000 people in the U.S. and up to 5.6 ...
/PRNewswire/ -- Boehringer Ingelheim's JASCAYD® (nerandomilast) tablets has been approved by the U.S. Food and Drug Administration (FDA) for the treatment of progressive pulmonary fibrosis (PPF) in ...
* In FIBRONEERTM-ILD, adverse events led to permanent discontinuation of the trial regimen in 10.0% of the JASCAYD 18 mg group, 8.1% in the JASCAYD 9 mg group, and 10.2% in the placebo group. 6 ...
Progressive pulmonary fibrosis (PPF) is a life-threatening, progressive lung condition, causing a continuous decline in lung function. 1, 2 Affecting up to 100,000 people in the U.S. and up to 5.6 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback